Cover Image
市場調查報告書

大便失禁 : 開發中產品分析

Fecal Incontinence - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 251636
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
大便失禁 : 開發中產品分析 Fecal Incontinence - Pipeline Review, H1 2016
出版日期: 2016年02月24日 內容資訊: 英文 43 Pages
簡介

大便失禁是指無法控制排便,讓排洩物由直腸漏出。造成大便失禁的一般原因有腹瀉,便秘,肌肉或神經病變等。症狀有腹瀉,便秘,放屁及脹滿等。治療方法有止洩藥,便秘藥,手術等。

本報告提供大便失禁的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

大便失禁 概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Celogos
  • Cook MyoSite Incorporated
  • Innovacell Biotechnologie AG
  • Juventas Therapeutics, Inc.
  • Norgine B.V.
  • RDD Pharma Ltd.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7598IDB

Summary

Global Markets Direct's, 'Fecal Incontinence - Pipeline Review, H1 2016', provides an overview of the Fecal Incontinence pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fecal Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fecal Incontinence and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fecal Incontinence
  • The report reviews pipeline therapeutics for Fecal Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fecal Incontinence therapeutics and enlists all their major and minor projects
  • The report assesses Fecal Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fecal Incontinence

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fecal Incontinence
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fecal Incontinence pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fecal Incontinence Overview
  • Therapeutics Development
    • Pipeline Products for Fecal Incontinence - Overview
  • Fecal Incontinence - Therapeutics under Development by Companies
  • Fecal Incontinence - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Fecal Incontinence - Products under Development by Companies
  • Fecal Incontinence - Companies Involved in Therapeutics Development
    • Celogos
    • Cook MyoSite Incorporated
    • Innovacell Biotechnologie AG
    • Juventas Therapeutics, Inc.
    • Norgine B.V.
    • RDD Pharma Ltd.
  • Fecal Incontinence - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ICEF-15 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methoxamine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxymetazoline hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RCD-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Fecal Incontinence - Recent Pipeline Updates
  • Fecal Incontinence - Dormant Projects
  • Fecal Incontinence - Product Development Milestones
    • Featured News & Press Releases
      • Jan 07, 2016: RDD Pharma Announces Additional Positive Results in a Double-Blind Placebo-Controlled Phase 2a Study in Fecal Incontinence
      • Oct 16, 2015: RDD Pharma Announces Positive Results in a Double-Blind Placebo-Controlled Crossover Phase 2a Study in Fecal Incontinence in Patients with Spinal Cord Injury
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fecal Incontinence, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Fecal Incontinence - Pipeline by Celogos, H1 2016
  • Fecal Incontinence - Pipeline by Cook MyoSite Incorporated, H1 2016
  • Fecal Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2016
  • Fecal Incontinence - Pipeline by Juventas Therapeutics, Inc., H1 2016
  • Fecal Incontinence - Pipeline by Norgine B.V., H1 2016
  • Fecal Incontinence - Pipeline by RDD Pharma Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Fecal Incontinence Therapeutics - Recent Pipeline Updates, H1 2016
  • Fecal Incontinence - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Fecal Incontinence, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top